Humana (NYSE:HUM) Earns Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Humana (NYSE:HUM) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $360.00 price objective on the insurance provider’s stock.

A number of other brokerages have also issued reports on HUM. Bank of America upped their price objective on shares of Humana from $342.00 to $376.00 and gave the company a neutral rating in a report on Monday, May 20th. Raymond James initiated coverage on Humana in a research report on Friday, March 22nd. They issued a market perform rating for the company. TD Cowen cut their price objective on Humana from $427.00 to $396.00 and set a buy rating for the company in a research report on Tuesday, April 2nd. Oppenheimer lowered their target price on shares of Humana from $415.00 to $370.00 and set an outperform rating for the company in a research note on Thursday, April 25th. Finally, Wells Fargo & Company decreased their price objective on shares of Humana from $413.00 to $350.00 and set an overweight rating on the stock in a report on Monday, April 8th. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $423.63.

Humana Price Performance

NYSE:HUM opened at $358.93 on Wednesday. The firm has a market cap of $43.25 billion, a P/E ratio of 22.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.53. The stock has a 50 day moving average of $336.24 and a two-hundred day moving average of $358.28. Humana has a 12 month low of $298.61 and a 12 month high of $530.54. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter last year, the firm posted $9.38 EPS. On average, analysts expect that Humana will post 16 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 0.99%. Humana’s dividend payout ratio is presently 22.04%.

Institutional Trading of Humana

Hedge funds and other institutional investors have recently made changes to their positions in the company. Barlow Wealth Partners Inc. purchased a new stake in Humana in the fourth quarter valued at approximately $1,977,000. Auxano Advisors LLC purchased a new stake in shares of Humana in the fourth quarter valued at about $540,000. Intech Investment Management LLC boosted its stake in shares of Humana by 46.2% during the fourth quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock worth $19,359,000 after buying an additional 13,356 shares during the period. AdvisorShares Investments LLC purchased a new position in shares of Humana during the fourth quarter worth about $421,000. Finally, Mariner LLC lifted its position in Humana by 2.3% during the 3rd quarter. Mariner LLC now owns 14,119 shares of the insurance provider’s stock worth $6,869,000 after acquiring an additional 312 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.